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Feline immunodeficiency virus (FIV) made defective in the accessory gene ORF-Awere previously shown to be greatly attenuated in its
ability to replicate in lymphocytes but to grow normally or near normally in other cell types. Here, we examined whether FIV thus mutated
could protect specific pathogen-free cats against challenge with ex vivo fully virulent homologous virus. No reversion of the vaccinating
infections to wild type ORF-A was noted over 22 months of in vivo infection. Following challenge, 6/6 unvaccinated control cats became
readily and heavily infected. In contrast, 3/9 vaccinees showed no evidence of the challenge virus over a 15-month observation period. In the
other vaccinees, the challenge virus was predominant for various periods of time, but pre-existing viral loads and CD4 lymphocyte counts
were either unaffected or altered only marginally and transiently. These findings show that ORF-A-defective FIV should be further examined
as a candidate live attenuated vaccine.
D 2004 Elsevier Inc. All rights reserved.
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Feline immunodeficiency virus (FIV) is both a natural
pathogen of the domestic cat and a widely used model to
evaluate potential approaches to AIDS vaccination (Bur-
khard and Dean, 2003; Elder et al., 1998; Uhl et al.,
2002; Willett et al., 1997). Similar to what has been
observed in primate models, to date inactivated whole virus
vaccines, subunit vaccines, and DNA vaccines have proved
ineffective or only marginally effective at controlling
challenge with fully virulent FIV (Bogers et al., 2000;
Hosie et al., 2000; Richardson et al., 1997; Uhl et al., 2002;
Willett et al., 1997). Live attenuated vaccines, which have
provided the strongest levels of protection against a variety
of uncloned natural pathogenic isolates in primate models,
have received limited scrutiny in the FIV model. Recently,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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tion was found to provide complete or partial protection
against heterologous intraclade challenge, depending on
whether challenge was administered intraperitoneally as
cell-free virus or intravaginally as cell-associated virus
(Pistello et al., 2003).
Safety is a major concern for use of live vaccines
(Blower et al., 2001; Nabel, 2002; Warren, 2002; Whitney
and Ruprecht, 2004). Attenuation by deleting accessory
genes dispensable for replication but necessary for full
virulence was conceived to render candidate simian
immunodeficiency virus (SIV) vaccines less likely to revert
to wild-type (wt) phenotype than the counterparts attenuated
by long-term propagation in vitro (reviewed in Kumar and
Narayan, 2001; Kuwata et al., 2001; Letvin et al., 2002;
Mills et al., 2000). This manipulation has indeed led to
greater levels of SIVattenuation than other strategies but has
nevertheless met with a number of unexpected difficulties.
A first attempt consisted in deleting nef alone, and an
attenuated virus was obtained which in adult macaques05) 676–690
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Desrosiers et al., 1998). Subsequently, this mutant was
however found to be pathogenic in neonate macaques (Baba
et al., 1995) and, over prolonged periods of observation,
even in adult animals (Chakrabarti et al., 2003; Hofmann-
Lehmann et al., 2003; Sawai et al., 2000). By contrast,
introducing multiple deletions in the accessory genes vpx,
vpr, and nef rendered SIV progressively more growth
attenuated but also increasingly unable to generate a
satisfactory degree of protection in vaccinated macaques,
most likely because it did not provide an adequate stimulus
to the immune system (Johnson et al., 1999; Wyand et al.,
1999). Thus, an attenuation strategy that overrides safety
concerns and affords sufficiently robust protection has yet to
be reported.
The ORF-A (also called ORF-2) of FIV is an auxiliary
gene that has been shown to have functions in common
with the accessory genes vpr, vpu, nef, and possibly tat of
HIV-1 and SIV (de Parseval and Elder, 1999; Gemeniano et
al., 2003, 2004; Inoshima et al., 1998; Tomonaga et al.,
1993, 1995). Important in the present context, deletions in
ORF-A have been shown to greatly impair the ability of
FIV to replicate productively in feline lymphocytes but to
leave replication in cell types such as monocyte-derived
macrophages (MDM) and fibroblasts essentially unaffected
(Gemeniano et al., 2003; Pistello et al., 2002; Waters et al.,
1996).
In previous work, we constructed and characterized
several ORF-A-defective mutants starting from a replica-
tion-competent molecular clone of FIV-Petaluma (FIV-Pet)
that exhibited the expected growth profile in vitro.
Furthermore, in cats, the ORF-A-defective mutants proved
highly attenuated, even when compared with the already
mild molecular clone from which they were derived.
Importantly, consistent with the results of in vitro character-
ization, MDM obtained from the peripheral blood mono-
nuclear cells (PBMC) of cats infected with ORF-A-
defective FIV exhibited levels of infection similar to those
found in cats infected with wt FIV while the lymphocyte-
enriched nonadherent counterpart showed very low copy
numbers throughout the observation period of 7 months. In
addition, repeated sequencing had shown that the mutants
had not reverted to the wt ORF-A (Pistello et al., 2002).
Collectively, these findings had indicated that the ORF-A-
defective mutants were still infectious for cats but had
produced low-grade infections which had greatly spared
lymphocytes.
Here, ORF-A-defective FIV was evaluated as a candidate
live vaccine. Theoretically, a virus thus attenuated may be
advantageous as a vaccine since its impaired replicative
capacity in lymphocytes is bound to greatly spare these cells
from becoming grossly depleted or deeply dysfunctional,
while its normal or near normal replication in other cell
types might guarantee the continued production of viral
antigen in quantities sufficient to keep anti-FIV immune
responses at protective levels.Results
Baseline virological and immunological status of the study
cats
The 18 specific pathogen-free (SPF) cats infected with
the ORF-A-defective FIV used in this study were derived
from a previous experiment in which the three ORF-A
mutants D07, D110, or D23 (6 cats each; heretofore
indicated as vaccinees) were evaluated for in vivo growth
properties (Pistello et al., 2002). The mutants were
derived by site-specific mutagenesis from the recombinant
plasmid p34TF10 containing the whole genome of the
prototype Petaluma strain of FIV (FIV-Pet; Gen Bank
Accession No. NC_001482; Talbott et al., 1989), carried a
7 amino acid deletion (D07), a stop codon and a 10 amino
acid deletion (D110), or 2 stop codons and a 3 amino acid
deletion (D23) within the ORF-A (Fig. 1A), and were
expanded in fibroblastoid Crandell feline kidney cells. Six
similar cats who had instead been infected with the
similarly manipulated wild-type ORF-A FIV D00 served
as controls for evaluating the extent of attenuation achieved
by ORF-A mutation. Because the vaccinees presented
uniformly mild infections pre-challenge (Tables 1 and 2)
and similar p.c. behavior (see below) regardless of the
specific viral mutant carried, they will be analyzed
separately for making the latter point but considered and
discussed as a single group.
Long-term dynamics of FIV infection in the unchallenged
vaccinees
To verify whether, as hypothesized, virus genetically
attenuated by ORF-A defects might lend itself to be used as
an FIV vaccine, a challenge was performed with fully
virulent homologous virus. To this purpose, 7 months post-
vaccination the D07, D110 and D23 vaccinees were split
into two subgroups, each of 3 cats, having baseline virolo-
gical and immunological conditions as closely matched as
possible (Tables 1 and 2). One subgroup was then
challenged intravenously with 10 cat infectious doses 50%
(CID50) of fully virulent ex vivo FIV-Pet, together with 5
age-matched naRve SPF cats who served as unimmunized
controls of the challenge. The other set was instead left
untreated to assess whether, with increasing time, the
infection status of the vaccines underwent changes that
might indicate a reduction in the extent of attenuation of the
infections and represent compounding factors in the
interpretation of challenge outcome. All groups were then
monitored for 15 months.
Follow-up of the unchallenged vaccinees confirmed
that their FIV infection was of low grade and remained so
throughout the entire period of observation (22 months in
total), regardless of the ORF-A mutant used for infection.
Steady-state plasma viremia and proviral loads rarely
exceeded 5,000 RNA copies per ml and 800 DNA copies
Fig. 1. Schematic of the 3 ORF-A detective FIV mutants used as attenuated vaccine (A) and mismatches between the env V3–V5 nucleotide sequences of the
FIV-Pet used as challenge and of p34TF10 from which the mutants were derived (B). The mismatches were exploited to discriminate the challenge from the
vaccine virus in the challenged vaccinees.
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values than detected in the parallel D00 controls (Fig. 2).
Virus re-isolation from the PBMC, performed by coculti-
vation with the feline lymphoid line MBM, was usually
successful but the numbers of infected cells was also
invariably low relative to what was found in D00 cats,
never exceeding 100 infectious units/106 PBMC (Table
2). Most importantly, analyses showed that, throughout
the observation period, the ORF-A-defective mutants
conserved the reduced lymphotropism associated to
unaltered replication in MDM they had exhibited during
the acute and post-acute phase of infection (Pistello et al.,2002). In particular, at all times and in all cats proviral
copy numbers associated to the MDM-enriched PBMC
were in the same range as in the D00 cats, whereas
proviral copy numbers in the lymphocyte-enriched PBMC
were much reduced and occasionally beneath detection
threshold (Figs. 3A and B). In addition, repeated sequen-
cing of plasma virus and PBMC provirus demonstrated
that the ORF-A region of the D07 and D23 mutants
remained exactly as initially mutagenized and that mutant
D110 underwent no further genetic modifications after the
ones detected during the first 7 months of follow up
(Pistello et al., 2002).
Table 2
FIV infectious units in the PBMC of the vaccinees and controls
Group Cat Infectious units per 106 PBMC at month
post-challenge
0 1 3 10 15
Cats infected with parental D00 virus (unchallenged)
D00 3074 NDa 102 102 –b ND
3085 ND 102 ND 102 ND
3097 ND 10 103 102 ND
3109 ND 10 103 102 102
3110 ND 102 102 103 102
3148 ND 102 10 10 102
Unchallenged vaccinees
D07 3104 – 102 10 10 1
3131 10 1 – 1 –
3143 1 10 102 102 1
D110 3078 – – – 1 1
3089 1 1 10 10 1
3114 1 10 10 10 1
D23 3092 10 1 1 1 –
3132 10 10 102 10 1
3138 – – 1 1 1
Challenged unvaccinated controls
487 – 103 103 102 –
505 – 103 103 102 10
2974 – 104 103 102 102
2979 – 102 102 102 ND
3079 – 102 102 10 ND
Challenged vaccinees
D07 506 1 10 102 102 1
3088 1 10 102 10 10
3103 1 102 10 10 10
D110 484 – 1 1 1 1
3119 1 1 1 102 102
3153 – 1 – 1 1
D23 3087 – 1 10 10 1
3093 10 102 102 102 –
3099 – 1 10 102 102
a ND, not done.
b –, Re-isolation culture negative.
Table 1
Virological and immunological status of the vaccinees at the time of
challenge
Group Cat FIV RNA
in seruma
FIV DNA
in PBMCb
ELISA
antibodyc
Circulating
CD4 +
T-cells
/Al blood (%)d
Cats infected with parental D00 virus
D00 3074 59710 1236 6400 702 (19)
3085 71250 386 3200 750 (20)
3097 64350 358 1600 878 (26)
3109 72130 2941 3200 1010 (30)
3110 69750 1945 800 915 (24)
3148 56250 1207 12800 757 (28)
Cats infected with ORF-A-defective virus
D07 506 2130 173 400 858 (37)
3088 4520 260 400 756 (31)
3103 1645 167 200 802 (34)
3104 850 255 100 909 (38)
3131 2100 305 400 1097 (31)
3143 3564 153 400 617 (32)
D110 484 5634 280 800 590 (32)
3078 5420 187 400 658 (36)
3089 2328 369 100 980 (34)
3114 3020 440 400 718 (35)
3119 2400 430 400 845 (40)
3153 5380 167 400 746 (34)
D23 3087 2850 310 200 879 (41)
3092 4686 320 400 1029 (38)
3093 6210 395 400 987 (33)
3099 b200 273 400 673 (34)
3132 7558 652 400 930 (40)
3138 2300 242 800 672 (36)
At this time, the D07, D110, and D23 vaccinees were divided into two
subgroups, one challenged and the other unchallenged, as specified in Table
2. For comparison, the status of parallel SPF cats inoculated with the wt
virus D00 is also shown.
a Copies per ml, as determined by RT-TaqMan-PCR. Note that the values
reported here are 3- to 8-fold higher than reported in Pistello et al. 2002,
since retesting showed that some artifact (possibly, a pitfall in the EDTA
solution used as anticoagulant) had somewhat reduced the sensitivity of
previous measurements. However, the differentials between the plasma
viremia levels of cats infected with ORF-A defective or wt viruses remained
unchanged.
b Load in 1 Ag of genomic DNA, as determined by TaqMan-PCR.
c Reciprocal of the highest serum dilution that scored positive against
whole FIV-Pet antigen.
d Normal values: 739 F 225 (35% F 5).
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immunological changes throughout the observation period.
The antibodies to whole FIV antigen, which had developed
slowly during the acute phase of infection (Pistello et al.,
2002), were generally low in titer but not substantially
different from what was seen in some D00 cats (Fig. 2C)
and FIV-specific lymphoproliferative responses were pos-
itive only sporadically like they had been earlier in infection
(data not shown). Finally, all vaccinees remained clinically
healthy as demonstrated by periodic clinic examination,
routine hematochemical analyses, and circulating CD4+ T
cell counts (Fig. 2D).Outcome of challenge: standard virological assays and
lymphocyte counts reveal little change over baseline levels
of infection in the vaccinees
As expected from previous studies (Pistello et al., 1999,
2002), the fully virulent ex vivo FIV-Pet stock used as
challenge readily established very sustained infections in all
the control unvaccinated cats. Plasma viremia peaked at
levels that in individual cats ranged between 248,320 and
118,940 copies per ml at 2 months post-challenge (p.c.) and
then decreased rapidly to stabilize at around 60,000 copies
per ml at 6 months p.c. (Fig. 4A). Proviral loads in the total
PBMC followed roughly parallel kinetics, showing the
highest values (30,440 to 127,847 copies per Ag of genomic
DNA) at 2 months p.c. in four cats and at 3 months p.c. in
one cat and subsequently declining to a mean steady-state
level of around 20,000 copies (Fig. 4B). Quantitative FIV
Fig. 2. Long-term follow-up of unchallenged cats vaccinated with the ORF-A mutants D07, D110, and D23 and in cats infected with wt ORF-A virus D00. Panels show: FIV RNA loads determined by RT-TaqMan-
PCR in plasma (A), FIV DNA copy numbers determined by TaqMan-PCR in total PBMC (B), antibody titers to whole FIV antigen determined by ELISA (C), and circulating CD4+ T-cells determined by flow
cytometry (D). Time 0 is when parallel groups of vaccinated animals were challenged with virulent virus. At this time, all animals had already been infected with the mutants or D00 for 7 months. The values
obtained at earlier samplings were already reported (Pistello et al., 2002).
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Fig. 3. Provirus loads in lymphocyte- (A and C) and MDM-enriched cell populations (B and D) obtained from the PBMC of the study cats by differential adherence to plastic. Panels represent: vaccinees infected
with the ORF-A-defective mutants and left unchallenged (A and B, 3 columns on the right), vaccinees infected with the wt ORF-A D00 virus and left unchallenged (A and B, left column), vaccinees infected with
the ORF-A-defective mutants and challenged with virulent ex vivo FIV (C and D, 3 columns on the right), and unvaccinated control cats given the same challenge (C and D, left column). The latter panels are
shadowed to draw attention on the different scale used. Time 0 is when the animals in panels C and D were challenged.
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Fig. 4. FIV infection course after challenge with fully virulent homologous virus in cats vaccinated with the ORF-A mutants D07, D110 and D23 and in unvaccinated control cats. Animals vaccinated 7 months
earlier with D07, D110, or D23 (3 cats per group) and unvaccinated animals (5 cats) were challenged with ex vivo FIV-Pet and then monitored at the indicated times. Panels as in Fig. 2. Asterisks and underlying
line indicate the time period during which the vaccinees had viral loads significantly lower than the unvaccinated controls at every sampling point (P b 0.01).
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M. Pistello et al. / Virology 332 (2005) 676–690 683re-isolation from the PBMC also showed high numbers of
infectious units especially during the acute phase (Table 2).
Anti-FIV antibodies became detectable by 1 month p.c. and
increased in titer steadily for 3 to 6 months to remain stable
thereafter (Fig. 4C). Finally, circulating CD4+ T cells
declined rapidly to approximately 50% of normal levels at
3 months and then rebounded slightly but remained
constantly well below pre-challenge values (Fig. 4D).
As determined by the above criteria, the course of
infection in the 9 challenged vaccinees was substantially
different. In fact, seven showed no appreciable changes in
plasma viral RNA and PBMC viral DNA copy numbers, and
the two who did (cats 506 and 3103, both of group D07)
showed an increase of plasma viremia above pre-challenge
values that lasted several months but never reached the levels
observed in the challenged control cats and eventually waned.
Furthermore, proviral loads (Fig. 4B) and numbers of FIV
infectious units in the PBMC (Table 2) remained unchanged
or increased only slightly. By contrast, most vaccinees
showed an increase of antibodies to whole FIV antigen
relative to baseline values, and this was generally evident
from the early months p.c., although in some it became
obvious only at later times (Fig. 4C). Positive FIV-specific
lymphoproliferative responses remained instead as scattered
as in the unchallenged vaccinees (data not shown). Finally,
CD4+ T cell counts were not appreciably affected by the
challenge, except in cats 506 and 3103 who showed a
moderate decline at 1 and 2 months p.c. but returned to pre-
challenge values at subsequent sampling points (Fig. 4D).
Collectively, these findings indicated that pre-infection with
ORF-A-defective FIV had substantially protected cats
against subsequent challenge with virulent homologous
virus.
Outcome of challenge: moderate proviral burden increases
in the lymphocyte-enriched fraction of PBMC point to a
changed infection course in some vaccinees
As discussed above, relative to the D00 animals, in
vaccinees the proviral loads of lymphocyte-enriched PBMC
were proportionally much more reduced than the proviral
loads of MDM-enriched PBMC. Because this appeared to
be a key feature of ORF-A-defective FIV, it was important
to assess whether challenge with fully virulent ex vivo FIV
could modify the situation in this respect. To this purpose,
the proviral burdens in the lymphocyte- and MDM-enriched
PBMC of the challenged animals were measured at all
sampling points. The results are shown in Figs. 3C and D,
where they can be easily compared with the already
discussed results of similar differential testing carried out
in the unchallenged vaccinees at the same time points (Figs.
3A and B). The general picture of 3 vaccinees (1 each in the
D07, D110, and D23 subgroups) did not change signifi-
cantly p.c., and in particular, their proviral burdens in the
lymphocyte-enriched PBMC remained as low as at baseline.
Contrariwise, in the other 6 vaccinees this parametershowed marked and variably protracted increases over the
pre-challenge values. Interestingly, these latter animals
included cats 506 and 3103, whose plasma viral loads had
clearly increased p.c., but also cats who had exhibited no
appreciable changes under this respect. It should be noted,
however, that in no vaccinee the peak provirus copy
numbers associated with the lymphocyte- or the MDM-
enriched PBMC ever approached those detected in the
challenged unvaccinated controls (Figs. 3C and D, left
column).
Sequence analysis reveals predominance of the vaccine or
the challenge virus in different cats
The above observation that proviral burdens in the
lymphocyte-enriched PBMC of some vaccinees had aug-
mented p.c. suggested that, in spite of unmodified or little
modified total plasma viral and total PBMC proviral loads,
these cats might have become infected by the challenge
virus. To verify this possibility, plasma virus obtained at
selected time points from all the challenged vaccinees was
amplified and directly sequenced in the ORF-A region. The
results showed that at the first sampling point, 1 month p.c.,
the ORF-A sequence obtained from 4/9 animals was of wt
genotype, and that at 3 months p.c. the same was true for 2
additional vaccinees (data not shown).
Because the animals where wt ORF-Awas detected were
exactly the same as the ones who had shown increased p.c.
proviral loads in the lymphocyte-enriched PBMC, the above
observation strongly suggested that in these animals the
challenge virus had indeed taken and was actually prevail-
ing over the vaccine virus. However, wt ORF-A detection in
such animals could also be explained by an albeit unlikely
reversion of the pre-infecting ORF-A-defective mutants to
wt genotype. Thus, characterization of the viruses present in
these animals was extended to direct sequencing the env
V3–V5 region which, due to a few mismatches between the
plasmid (p34TF10) used for producing the ORF-A-defec-
tive mutants and the challenge virus (Fig. 1B), allowed an
unequivocal discrimination of the two viruses. Furthermore,
to attain a more complete picture, the analysis was carried
out on provirus obtained from lymphocyte- and MDM-
enriched PBMC and from the re-isolation cultures as well as
on plasma virus. From examination of Fig. 5A, which
summarizes these results, the following major points can be
gathered: (1) in all instances the V3–V5 sequences
confirmed the vaccine or challenge origin of the viruses
gathered from the less extensive ORF-A sequencing
discussed above; (2) in three vaccinees, precisely the ones
who had shown no increases in lymphoid-enriched PBMC
proviral loads, direct V3–V5 sequencing showed no
evidence of the presence of the challenge virus at any
sampling point; (3) in the other 6 vaccinees, starting at 1 or
3 months p.c., the challenge virus dominated up to the end
of the follow-up (four cats) or for a variably long period of
time (two cats); (4) there was an almost 100% overall
Fig. 5. Origin of the virus prevailing in the vaccinees at different times p.c. Discrimination between vaccine (5) and challenge virus (n) was carried out by direct sequencing (A) or cloning and sequencing (B) the
env V3–V5 region on plasma virus (P) and provirus obtained from lymphocyte-enriched PBMC (L), MDM-enriched PBMC (M), and re-isolation cultures (C). Vaccine and challenge virus were identified by the
mismatches shown in Fig. 1B.
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M. Pistello et al. / Virology 332 (2005) 676–690 685concordance between the results of genotyping virus in
plasma or provirus, regardless of the source from which this
was obtained, thus showing the validity of the genotyping
approach used.
The findings above had shown that, although the overall
levels of FIV infection of the vaccinees had changed little
p.c., the challenge virus was handled differently in different
animals: in some, it had taken so effectively as to become
more represented than the vaccine virus through the end of
the observation period, in others, it had remained constantly
overshadowed by the vaccine virus, and in still others, it had
become transiently predominant followed by the re-emer-
gence of vaccine virus. Because the latter two categories of
cats appeared particularly interesting, an estimate of the
relative amounts of the vaccine and challenge virus they
harbored was determined. This was achieved by cloning the
env amplicons obtained at selected time points from plasma
and lymphocyte-enriched PBMC and sequencing 10–12
clones for each viral sample. The env and not the ORF-A
region was chosen for this study because the latter, being
shorter in the vaccine than in the challenge virus, did not
guarantee an unbiased efficiency of amplification of the
two. As shown by Fig. 5B, the viral samples that by direct
sequencing had been invariably found positive for the
vaccine virus yielded clones of this same genotype, thus
showing that in these samples the vaccine largely exceeded
the challenge virus. A mixed vaccine/challenge infection
was detected only in one vaccinee in whom by direct
sequencing the challenge virus had emerged only transi-
ently, cat 3093, and this occurred only with the sample taken
6 months p.c., the last sample tested before re-emergence of
the vaccine virus.Discussion
ORF-A-defective FIV is attractive as a candidate live
vaccine because its replication in lymphocytes is impaired.
This potential for greatly sparing immune functions in
infected hosts but still being competent for replication in
other cell types presumably should allow continued
production of sufficient antigen to keep the host’s defenses
properly stimulated. Studies using SIV in macaques have
clearly shown that the latter is a critical determinant of
protection by attenuated vaccines (Johnson et al., 1999;
Wyand et al., 1999). In this investigation, we explored ORF-
A-defective FIV with regard to stability of attenuated traits
over a prolonged period of infection in natural hosts and
ability to afford the same hosts with substantial protection
against virulent homologous virus.
The subjects were 18 SPF cats that are discussed here as
a single group since they showed indistinguishable features,
both pre- and post-challenge, but had been inoculated with
three distinct FIV mutants having the ORF-A disrupted by
one or two stop codons and/or deletions of varying length.
As detailed in a previous report (Pistello et al., 2002),throughout the pre-challenge period of 7 months, all (i)
carried infections of similarly very moderate grade, (ii)
displayed normal peripheral blood lymphocyte numbers and
subsets, and (iii) showed no evidence of ORF-A reversion to
wt, even though one specific mutant had undergone
extensive ORF-A changes during the acute phase of
infection. In the present continuation of such follow-up,
none of 9 vaccinees who were left unchallenged showed
changes that might suggest or forecast a possible evolution
toward increased severity of infection. In particular,
throughout the additional 15 months of observation, these
cats continued to yield no wt ORF-A, as determined by
repeated sequencing, and to exhibit what had previously
been shown to be a hallmark of infection with ORF-A-
defective FIV, namely proviral loads that were greatly
reduced in lymphocyte-enriched PBMC relative to MDM-
enriched PBMC, compared to what was observed with wt
FIV. Thus, the prerequisite of genetic and phenotypic
stability of attenuation was respected.
Protective efficacy was tested by intravenously inoculat-
ing the other 9 vaccinees (3 from each mutation group) with a
plasma preparation of homologous virus which, in addition to
possessing a wt ORF-A, had been readapted to in vivo growth
by consecutive passages in cats. As expected based on
previous results (Pistello et al., 2003), in age-matched
unvaccinated control cats this challenge infected 5/5 recip-
ients who underwent a concomitant rapid and profound
depletion of circulating CD4+ cells (a well recognized marker
of FIV pathogenicity) which rebounded only slightly in the
post-acute phase of infection. In contrast, over the 15 months
of p.c. follow-up, the vaccinees either exhibited no appreci-
able changes in pre-existing viral set points (7/9 cats) or
showed a moderate and transient increase of plasma viremia
at 3 and 6 months p.c. that was not accompanied by increased
proviral loads (2/9 cats). In addition, with the exception of a
transient small dip in the two cats whose plasma viremia
levels had slightly increased, blood lymphocyte subset counts
of the vaccinees were unaffected by the challenge.
Thus, based on the above results, ORF-A-defective FIV
had apparently fulfilled the prerequisites of an attenuated
vaccine also with regard to overall protective activity. There
were, however, hints that protection had not been complete
and had allowed take of the challenge virus in at least some
vaccinees. The hints consisted of a general increase of anti-
FIV antibodies over pre-challenge levels, the already
discussed marginal but significant changes in plasma viral
loads and CD4+ T cell counts observed in two cats, and the
finding that in six animals the proviral loads of lymphocyte-
enriched PBMC no longer were as low as they had been
prior to challenge. Characterization of the virus harbored
p.c. by the vaccinees showed that, in fact, the resistance
afforded by the vaccine had not necessarily prevented
superinfection. Indeed, while 3 animals revealed no
evidence of the challenge virus in any sampling, thus
showing that this either had not taken or had remained
masked by an excess of the pre-existing vaccine virus, the
M. Pistello et al. / Virology 332 (2005) 676–690686others unequivocally yielded the challenge virus either
transiently (3 cats) or throughout the entire p.c. observation
period (remaining 3 cats).
That immunization with attenuated antilentiviral vac-
cines can fail to prevent the take of challenge viruses and
nevertheless reduce their extent of replication and patho-
logical effects has repeatedly been observed in primate
models (Blancou et al., 2004; Khatissian et al., 2001;
Kumar et al., 2002; Kwofie et al., 2002; Marthas et al.,
1990; Mori et al., 2001; Shacklett et al., 2002; Stahl-
Hennig et al., 2003; Van Rompay et al., 2003; Wyand et
al., 1999) and most recently has been seen in FIV as well
(Pistello et al., 2003). In most vaccinated cats, the virulent
ex vivo FIV used as challenge in the present study not
only established itself but also predominated over the
vaccine virus for months or throughout the observation
period, possibly as a result of the fact that it found the
lymphoid compartment largely unoccupied by the pre-
infecting ORF-A-defective virus. Yet, the superimposed
virus produced very little change or none at all in pre-
existing levels of infection and very marginal or no signs
of disease, thus indicating that the ORF-A-defective FIV
had created a situation in which a superinfecting highly
virulent homologous virus could express very little if any
of its intrinsic pathogenic potential. The effectors that were
at work in such containment are unclear. Although
attenuated antilentiviral vaccines have often been regarded
as important study systems for pinpointing immune
correlates of protection against HIV and other lentiviruses
(Johnson and Desrosiers, 1998; Whitney and Ruprecht,
2004), the entire area of the mechanisms underlying their
unsurpassed protective efficacy is poorly understood (Abel
et al., 2003; Bigornia et al., 2001; Blancou et al., 2004;
Broussard et al., 2001; Connor et al., 1998; Gundlach et
al., 1998; LaFranco-Scheuch et al., 2004; Lockridge et al.,
2000; Nixon et al., 2000; Pistello et al., 1999; Stebbings et
al., 2002). The mechanisms of protection by ORF-A
deleted FIV are no exception. By greatly sparing lympho-
cytes, theoretically, the ORF-A deleted FIV could have led
to development of adaptive immune responses and
possibly nonadaptive defense mechanisms of an efficacy
not achievable by a fully lymphotropic virulent virus;
however, standard assays revealed that humoral and cell-
mediated immune responses were weak in the vaccinees
prior to challenge (Pistello et al., 2002). Viral interference
and suppression of FIV replication by cytolytic and
noncytolytic cells and soluble factors are obvious candi-
date effectors (DeVico and Gallo, 2004; Flynn et al., 1999;
Gebhard et al., 1999; Phadke et al., 2004; Vahlenkamp et
al., 2004; VandeWoude et al., 2003), but others still
undefined cannot be excluded. It is worth recalling that in
previous work, an attenuated FIV proved unable to prevent
superinfection by a virulent FIV of a different clade but,
after a period during which the superinfecting virus
dominated, eventually, the attenuated FIV again became
the dominant infection, in the absence of detectableclassical immune effectors that could justify the shift
(Pistello et al., 1999). In any case, it is remarkable that in
the present study whenever direct sequencing indicated
that the vaccine virus was predominating over the
challenge virus, cloning and sequencing studies showed
that the extent by which this occurred was substantial. This
indicated that the equilibrium the ORF-A-defective FIV
had reached with the host was quite stable and could not
be easily modified by superinfection, even by a much
more virulent virus.
It is difficult to translate the present findings to human
AIDS, since in HIV-1 there is no accessory gene needed for
unrestricted virus replication in lymphocytes but irrelevant
for replication in other cell types as is the ORF-A for FIV.
Together with clear evidence that the extent of HIV-1
replication during the earliest phase of infection prior to the
mounting of immune responses dictates clinical outcome
and disease progression (Blattner et al., 2004; Letvin and
Walker, 2003), they however clearly indicate that manipu-
lating HIV-1 in such a way as to stably reduce its replication
competence in lymphocytes but not in other cell types might
be of considerable advantage in the development of live
attenuated AIDS vaccines. Although at this time attenuated
vaccines are not considered feasible for fighting AIDS due
to safety concerns, in the future, this consideration might
change with the growing alarm generated by the ever-
expanding AIDS pandemic and development of improved
attenuated vaccines. Field testing (Matteucci et al., 1999)
attenuated live FIV vaccines in domestic cats might help in
assessing the actual risk associated with this form of
vaccination.Material and methods
Animals and viruses
The female SPF cats (Iffa Credo, L’Asbresle, France)
used for this study were 10 month old and serologically free
from FIV and feline leukemia virus at the commencement
of the study. They were housed in our climate-controlled
animal facility under European Community law conditions
and randomly assigned to five experimental groups.
Generation of the ORF-A FIV mutants and wt D00 FIV
has been described (Pistello et al., 2002). Inoculation of
cats with these viruses was carried out subcutaneously at
400 50% tissue culture infectious doses per cat. Challenge
virus was uncloned FIV-Pet which had been readapted to in
vivo growth by several consecutive passages in cats
(Giannecchini et al., 2001) and, as a result, was much
more virulent than the in vitro propagated counterparts.
Challenge was carried out by intravenous administration of
cell-free plasma from acutely infected cats at 10 CID50.
This challenge was known to consistently infect naRve cats
and to produce florid infections and rapid falls of
circulating CD4+ T cells.
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Plasma viremia was evaluated by extracting RNA with
the QIAamp Viral RNA kit (Qiagen, Milan, Italy) according
to the protocol provided by the manufacturer. The same
procedure was also applied with serum samples collected
before challenge. Ten Al of RNA extracted from plasma
were reverse-transcribed in 20 Al with 900 nM antisense
primer PU8-AS TGAATAATCTTCCTTAGCTCCTTGTCT
(1467–1493), 5 U avian myeloblastosis virus RT (Promega,
Milan, Italy), and 8 U RNase inhibitor (Promega). The
cDNA was then amplified by TaqMan-PCR on the ABI
Prism 7700 Sequence Detection System instrument
(Applied Biosystems, Monza, Italy) with the Universal
PCR Master Mix (Applied Biosystems), 900 nM sense
primer PU8-S CACCAGCTAGGATGCAGTGTAGA (nt
position 1375–1397), and 200 nM probe PU8-P TTGGCTQ
GCCATAAAAGCTAAGTCTCCTCG (1425–1453). Sam-
ples and negative and positive controls were tested in
triplicate. Amplification settings and precautions to avoid
misquantitation have been previously described (Pistello et
al., 2003). Serial ten-fold dilutions (102 to 107) of gag p24
FIV-Pet RNA produced by run-off transcription of pGEM/
Pet were used to produce a standard curve. All the
samples positive in only one replica and/or with a
coefficient of variation of V50% were re-extracted and
tested again in triplicate. Sensitivity was 200 copies per ml,
as determined by extracting and amplifying FIV-negative
plasma spiked with serial ten-fold dilutions of FIV-Pet RNA
transcripts.
Proviral load quantitation
Genomic DNA was extracted from the cells under
scrutiny using a commercial kit (QIAamp DNA Blood
Mini Kit; Qiagen) following manufacturer’s instructions.
Extracted DNA (0.2–0.6 Ag) was tested for competence for
amplification and provirus DNA quantitated by TaqMan-
PCR as described in detail elsewhere (Pistello et al., 1999),
and provirus DNA quantitated by TaqMan-PCR under the
conditions described above, except that reaction volume was
25 Al. Serial ten-fold dilutions (101 to 107) of p34TF10 in a
background of 1 Ag of genomic DNAwere used to produce
a standard curve and determine the lowest limit of detection
(10 copies).
Virus genotyping
Discrimination between the ORF-A mutated viruses and
the wt challenge virus was done by cycle sequencing the
ORF-A and V3–V5 env regions, starting from genomic
DNA extracted from virus-positive cells or from viral RNA
extracted from plasma. The sequences of the intact and
mutagenized ORF-A are available elsewhere (Pistello et al.,
2002). The distinguishing segments of V3–V5 are shown by
Fig. 1. ORF-A and V3–V5 amplifications were carried outby using specific primer sets and hemi-nested and nested
PCR, respectively. Likewise, virus RNA was reverse tran-
scribed with ORF-A and V3–V5 specific antisense primers.
Amplified products were then checked by agarose gel
electrophoresis and, whenever a single amplicon was
present, directly analyzed by cycle sequencing using the
automated ALF ExpressII DNA sequencer (Amersham
Biosciences, Cologno Monzese, Italy) and ORF-A and
env sequencing primers. If multiple amplicons were present
on agarose gel, they were separated either by cutting gel
slices or touching each band with the tip of a needle.
Separated fragments were then reamplified with the inner
primers, electrophoresed on agarose gel and, in the presence
of a single band, sequenced. Each sample was amplified and
sequenced twice on different occasions. Nucleotide sequen-
ces were then aligned and compared and, if they were
discordant, the whole amplification and sequencing process
was repeated. When indicated, V3–V5 amplicons were
cloned into pCRII T-vector and processed as indicated by
the manufacturer (Invitrogen Italia, San Giuliano Milanese,
Italy), and individual clones sequenced as described above.
Virus isolation and infectious cell enumeration
For FIV re-isolation from infected cells, 106 Ficoll-Paque
gradient purified PBMC were stimulated with Concanava-
lin-A (Sigma-Aldrich, Milan, Italy) and cocultured with 106
cells of the feline T-lymphoid line MBM in RPMI 1640
medium containing 10% fetal bovine serum and 10 U/ml
human recombinant IL-2 (Roche Diagnostics, Monza,
Italy). Culture supernatants were monitored biweekly for
p25 and RT production by ELISA for up to 5 weeks as
previously described (Matteucci et al., 1999). Quantitation
of circulating infectious units was performed exactly as
described above except that the co-cultures were established
with ten-fold serial dilutions of the PBMC under scrutiny.
Lymphocyte- and MDM-enriched PBMC
Freshly harvested Ficoll-Paque gradient purified PBMC
were cultured at 2  106 cells per ml in complete RPMI
1640 medium. After 24 h in culture, nonadherent and
adherent cells were separated by vigorous agitation, washed
three times with abundant phosphate-buffered saline, and
used as source of lymphocyte-enriched and MDM-enriched
DNA, respectively. As determined by May-Grqnwald-
Giemsa staining, purity of the two cell populations was
80% and 70%, respectively. MDM lysis was carried out
directly in the culture wells.
Serology
Plasma was tested for antibody against whole FIV-Pet
antigen by ELISA as described (Matteucci et al., 1997).
Plasma specimens found reactive at dilutions 1:100 or
greater were considered antibody-positive.
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Ficoll-purified PBMC were incubated for 4 days with
0.1 Ag of gradient-purified sonicated FIV-Pet grown in FL-
4 cells (Yamamoto et al., 1991) and then pulsed with [3H]-
thymidine for 18 h (Matteucci et al., 1999). Stimulation
indexes z2, calculated as the ratio of radioactivity
incorporated by PBMC in the presence or absence of
FIV antigen, were considered indicative of FIV-specific
lymphoproliferation.
Hematology and lymphocyte subset analysis
Complete blood counts and differential leukocyte counts
were performed by standard methods. CD4+ and CD8+ T
cell counts were determined by flow cytometry using a
FACScan (BD Biosciences-Life Science Research, Milan,
Italy).
Statistical analysis
Statistical significance of the differences between groups
was determined using the Student’s unpaired t test assuming
equal variances. P values of less than 0.05 were considered
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